Repros Therapeutics Company Profile (NASDAQ:RPRX)

About Repros Therapeutics (NASDAQ:RPRX)

Repros Therapeutics logoRepros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:RPRX
  • CUSIP: 76028H20
  • Web: www.reprosrx.com
Capitalization:
  • Market Cap: $14.41 million
  • Outstanding Shares: 26,679,000
Average Prices:
  • 50 Day Moving Avg: $0.91
  • 200 Day Moving Avg: $1.27
  • 52 Week Range: $0.51 - $2.48
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.74
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.24 per share
  • Price / Book: 2.25
Profitability:
  • EBIDTA: ($17,320,000.00)
  • Net Margins: -39,128.00%
  • Return on Equity: -151.63%
  • Return on Assets: -127.79%
Debt:
  • Current Ratio: 4.63%
  • Quick Ratio: 4.63%
Misc:
  • Average Volume: 151,198 shs.
  • Beta: -0.82
  • Short Ratio: 6.39
 

Frequently Asked Questions for Repros Therapeutics (NASDAQ:RPRX)

What is Repros Therapeutics' stock symbol?

Repros Therapeutics trades on the NASDAQ under the ticker symbol "RPRX."

How were Repros Therapeutics' earnings last quarter?

Repros Therapeutics Inc (NASDAQ:RPRX) announced its earnings results on Tuesday, May, 9th. The company reported ($0.22) EPS for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.08. The firm earned $0.01 million during the quarter. Repros Therapeutics had a negative return on equity of 151.63% and a negative net margin of 39,128.00%. View Repros Therapeutics' Earnings History.

Where is Repros Therapeutics' stock going? Where will Repros Therapeutics' stock price be in 2017?

1 equities research analysts have issued 12 month target prices for Repros Therapeutics' shares. Their forecasts range from $1.50 to $1.50. On average, they expect Repros Therapeutics' share price to reach $1.50 in the next twelve months. View Analyst Ratings for Repros Therapeutics.

Who are some of Repros Therapeutics' key competitors?

Who owns Repros Therapeutics stock?

Repros Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (5.95%), Vanguard Group Inc. (3.34%), Sphera Funds Management LTD. (2.92%), Renaissance Technologies LLC (2.73%), General American Investors Co. Inc. (2.21%) and Allegis Investment Advisors LLC (1.37%). View Institutional Ownership Trends for Repros Therapeutics.

Who sold Repros Therapeutics stock? Who is selling Repros Therapeutics stock?

Repros Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD. and FMR LLC. View Insider Buying and Selling for Repros Therapeutics.

Who bought Repros Therapeutics stock? Who is buying Repros Therapeutics stock?

Repros Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Allegis Investment Advisors LLC, Renaissance Technologies LLC, Vanguard Group Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Repros Therapeutics.

How do I buy Repros Therapeutics stock?

Shares of Repros Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Repros Therapeutics stock cost?

One share of Repros Therapeutics stock can currently be purchased for approximately $0.54.

Analyst Ratings

Consensus Ratings for Repros Therapeutics (NASDAQ:RPRX) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $1.50 (177.78% upside)

Analysts' Ratings History for Repros Therapeutics (NASDAQ:RPRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/30/2017S&P Equity ResearchBoost Price Target$1.22 -> $1.50N/AView Rating Details
11/16/2016Ladenburg Thalmann Financial ServicesUpgradeNeutral -> BuyN/AView Rating Details
2/9/2016Piper Jaffray CompaniesReiterated RatingNeutralN/AView Rating Details
12/4/2015Brean CapitalReiterated RatingHoldN/AView Rating Details
10/30/2015Bank of America CorpDowngradeNeutral -> UnderperformN/AView Rating Details
7/28/2015LaidlawReiterated RatingBuy$28.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Repros Therapeutics (NASDAQ:RPRX)
Earnings by Quarter for Repros Therapeutics (NASDAQ:RPRX)
Earnings History by Quarter for Repros Therapeutics (NASDAQ:RPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.15)($0.22)$0.01 millionViewN/AView Earnings Details
3/31/2017Q4 2016($0.17)($0.16)$0.01 millionViewN/AView Earnings Details
11/8/2016Q3 2016($0.18)($0.17)$0.01 millionViewN/AView Earnings Details
8/9/2016Q216($0.20)($0.18)$0.02 millionViewN/AView Earnings Details
5/10/2016Q1($0.22)($0.20)$0.02 millionViewN/AView Earnings Details
3/14/2016Q4($0.27)($0.26)$0.01 millionViewN/AView Earnings Details
11/9/2015Q3($0.29)($0.27)ViewN/AView Earnings Details
8/10/2015Q2($0.26)($0.32)ViewN/AView Earnings Details
3/16/2015Q414($0.34)($0.31)ViewN/AView Earnings Details
11/10/2014Q314($0.39)($0.32)ViewN/AView Earnings Details
8/11/2014($0.37)($0.38)ViewN/AView Earnings Details
5/12/2014Q114($0.35)($0.37)ViewN/AView Earnings Details
3/13/2014Q413($0.29)($0.31)ViewN/AView Earnings Details
8/7/2013Q213($0.40)($0.38)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.35)($0.41)ViewN/AView Earnings Details
3/18/2013Q412($0.28)($0.47)$0.00 million$0.00 millionViewN/AView Earnings Details
11/13/2012Q312($0.24)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Repros Therapeutics (NASDAQ:RPRX)
Current Year EPS Consensus Estimate: $-0.76 EPS
Next Year EPS Consensus Estimate: $-0.73 EPS

Dividends

Dividend History for Repros Therapeutics (NASDAQ:RPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Repros Therapeutics (NASDAQ:RPRX)
Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 27.04%
Insider Trades by Quarter for Repros Therapeutics (NASDAQ:RPRX)
Institutional Ownership by Quarter for Repros Therapeutics (NASDAQ:RPRX)
Insider Trades by Quarter for Repros Therapeutics (NASDAQ:RPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Joseph PodolskiInsiderBuy20,000$1.60$32,000.00View SEC Filing  
2/18/2016Joseph PodolskiCEOBuy10,000$0.93$9,300.00View SEC Filing  
1/7/2016Joseph PodolskiCEOBuy11,677$1.18$13,778.86View SEC Filing  
11/12/2014Joseph PodolskiCEOBuy4,700$9.42$44,274.00View SEC Filing  
11/12/2014Katherine AndersonCFOBuy3,500$9.41$32,935.00View SEC Filing  
8/14/2014Joseph PodolskiCEOBuy2,100$13.91$29,211.00View SEC Filing  
8/14/2014Katherine AndersonCFOBuy2,000$13.85$27,700.00View SEC Filing  
10/25/2013Joseph PodolskiCEOBuy3,000$18.03$54,090.00View SEC Filing  
10/25/2013Katherine AndersonCFOBuy1,000$17.90$17,900.00View SEC Filing  
10/10/2013Katherine AndersonCFOBuy1,000$23.77$23,770.00View SEC Filing  
2/1/2013Katherine AndersonCFOBuy1,000$11.89$11,890.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Repros Therapeutics (NASDAQ:RPRX)
Latest Headlines for Repros Therapeutics (NASDAQ:RPRX)
Source:
DateHeadline
globenewswire.com logoRepros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock - GlobeNewswire (press release)
globenewswire.com - May 18 at 10:57 AM
streetinsider.com logoRepros Therapeutics (RPRX) Plans Offering of Common Stock, Warrants - StreetInsider.com
www.streetinsider.com - May 18 at 10:57 AM
finance.yahoo.com logoRepros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock
finance.yahoo.com - May 18 at 10:57 AM
streetinsider.com logoRepros Therapeutics (RPRX) Plans Offering of Common Stock, Warrants
www.streetinsider.com - May 17 at 7:32 PM
finance.yahoo.com logoRepros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
finance.yahoo.com - May 17 at 7:32 PM
globenewswire.com logoRepros Therapeutics Inc.® Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 10 at 7:50 PM
americanbankingnews.com logoRepros Therapeutics Inc (RPRX) Announces Quarterly Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - May 10 at 6:40 PM
finance.yahoo.com logoRepros Therapeutics Inc.® Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 7:07 PM
marketbeat.com logoRepros Therapeutics reports 1Q loss
marketbeat.com - May 9 at 5:44 PM
nasdaq.com logoWhat's in the Cards for Repros (RPRX) this Earnings Season? - Nasdaq
www.nasdaq.com - May 6 at 12:55 AM
zacks.com logoWhat's in the Cards for Repros (RPRX) this Earnings Season?
www.zacks.com - May 5 at 7:54 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Extremely Likely to Impact Repros Therapeutics (RPRX) Stock Price
www.americanbankingnews.com - May 4 at 2:26 PM
americanbankingnews.com logoRepros Therapeutics (RPRX) Given Daily News Impact Score of 0.04
www.americanbankingnews.com - May 1 at 3:26 PM
americanbankingnews.com logoRepros Therapeutics (RPRX) Receives Daily News Impact Rating of 0.26
www.americanbankingnews.com - April 28 at 4:38 PM
americanbankingnews.com logoPositive Media Coverage Extremely Likely to Impact Repros Therapeutics (RPRX) Share Price
www.americanbankingnews.com - April 24 at 3:26 PM
americanbankingnews.com logoRepros Therapeutics (RPRX) Earning Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 21 at 6:09 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Extremely Likely to Impact Repros Therapeutics (RPRX) Share Price
www.americanbankingnews.com - April 17 at 7:25 PM
finance.yahoo.com logoRepros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions
finance.yahoo.com - April 17 at 6:40 PM
americanbankingnews.com logoRepros Therapeutics Inc (RPRX) Short Interest Up 0.0% in March
www.americanbankingnews.com - April 13 at 4:50 PM
americanbankingnews.com logoRepros Therapeutics (RPRX) Receiving Somewhat Positive News Coverage, Analysis Finds
www.americanbankingnews.com - April 13 at 12:26 PM
finance.yahoo.com logoRepros' Proellex Continues to be Under Partial Clinical Hold
finance.yahoo.com - April 11 at 7:24 PM
zacks.com logoRepros' Proellex Continues to be Under Partial Clinical Hold
www.zacks.com - April 11 at 9:58 AM
finance.yahoo.com logoWoodlands drug company names new top exec
finance.yahoo.com - April 11 at 9:58 AM
streetinsider.com logoRepros Therapeutics (RPRX) Names Larry Dillaha as CEO
www.streetinsider.com - April 10 at 7:06 PM
finance.yahoo.com logoRepros Therapeutics stock halted after FDA says partial clinical hold will continue for fibroids drug
finance.yahoo.com - April 10 at 7:06 PM
seekingalpha.com logoFDA continues partial clinical hold for Repros Therapeutics' fibroids drug
seekingalpha.com - April 10 at 10:22 AM
finance.yahoo.com logoCompany Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids
finance.yahoo.com - April 10 at 9:23 AM
finance.yahoo.com logoRepros Names Larry Dillaha, M.D., its Permanent President and CEO
finance.yahoo.com - April 10 at 9:23 AM
americanbankingnews.com logoRepros Therapeutics Inc (RPRX) Announces Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - April 3 at 7:32 AM
us.rd.yahoo.com logoRepros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results
us.rd.yahoo.com - March 31 at 7:46 PM
biz.yahoo.com logoREPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition
us.rd.yahoo.com - March 31 at 7:46 PM
americanbankingnews.com logoRepros Therapeutics Inc (RPRX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - March 11 at 12:42 AM
nasdaq.com logoRepros (RPRX) Q4 Earnings: What's in Store for the Stock? - Nasdaq
www.nasdaq.com - March 8 at 7:52 PM
finance.yahoo.com logoRepros (RPRX) Q4 Earnings: What's in Store for the Stock?
finance.yahoo.com - March 7 at 7:29 PM
biz.yahoo.com logoREPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi
biz.yahoo.com - February 8 at 11:34 PM
streetinsider.com logoRepros Therapeutics (RPRX) Names Larry Dillaha as Interim CEO - StreetInsider.com
www.streetinsider.com - February 4 at 7:41 PM
bizjournals.com logoCEO leaves Woodlands-based drug company; interim named
www.bizjournals.com - February 3 at 11:38 PM
streetinsider.com logoRepros Therapeutics (RPRX) Names Larry Dillaha as Interim CEO
www.streetinsider.com - February 3 at 3:10 AM
us.rd.yahoo.com logo9:16 am Repros Therapeutics President and CEO Joseph S. Podolski is leaving his position to pursue other interests; Larry Dillaha, M.D., CEO of CavtheRx, was appointed interim President and CEO, effective immediately
us.rd.yahoo.com - February 3 at 3:10 AM
streetinsider.com logoRepros Therapeutics (RPRX) Granted FDA End of Phase 2 Meeting on Proellex
www.streetinsider.com - February 1 at 3:11 AM
streetinsider.com logoRepros Therapeutics (RPRX) Granted FDA End of Phase 2 Meeting on Proellex - StreetInsider.com
www.streetinsider.com - January 30 at 8:25 PM
finance.yahoo.com logo9:15 am Repros Therapeutics announces that the FDA has granted an 'end of Phase 2' meeting to discuss the Phase 3 requirements to demonstrate both efficacy and safety for the development of Proellex for the treatment of uterine fibroids
finance.yahoo.com - January 30 at 8:25 PM
finance.yahoo.com logoFDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids
finance.yahoo.com - January 30 at 8:25 PM

Social

Chart

Repros Therapeutics (RPRX) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff